Form 4: Spyre Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Heidy King-Jones, Chief Legal Officer and Corporate Secretary of Spyre Therapeutics, was granted stock options for 95,500 shares.
Summary
- Heidy King-Jones, Chief Legal Officer and Corporate Secretary at Spyre Therapeutics, was granted stock options to purchase 95,500 shares of the company's common stock.
- The options have an exercise price of $21.66 per share.
- The options vest in equal monthly installments over four years, contingent on continued employment with Spyre Therapeutics.
- The options expire on January 15, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Risks
- The value of the stock options is dependent on the future performance of Spyre Therapeutics' stock price.
- If the executive leaves the company before the options fully vest, they may forfeit some or all of the options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in the biotech industry.
- The vesting schedule of four years is typical for such grants, ensuring long-term commitment.
- The exercise price is set at a specific value, which is common practice.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes management to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/15/2025 | Date of the stock option grant and the start of the vesting period. |
| 01/17/2025 | Date of the filing of the SEC Form 4. |
| 01/15/2035 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, equity, vesting, Spyre Therapeutics, SYRE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.